Ildong Pharmaceutical Receives Approval for Phase 1 Clinical Trial of ‘ID110521156’ – A Promising Drug Candidate for Metabolic Diseases
[이데일리 김진수 기자] Ildong Pharmaceutical announced on the 6th that it has received approval from the Ministry of Food and Drug Safety for phase 1 clinical trial of ‘ID110521156’, a new drug candidate in the field of metabolic diseases with a mechanism of GLP-1 receptor agonist. Ildong Pharmaceutical Headquarters. (Photo = Ildong Pharmaceutical) Ildong Pharmaceutical … Read more